Jennifer N Choi, Mario Lacouture, Anneke Andriessen, Alice Ho, Beth McLellan, Edith Mitchell, Jonathan Leventhal
{"title":"INDIVIDUAL ARTICLE: USCOM V: A Practical Algorithm for the Prevention and Treatment of Cutaneous Side Effects of Hormonal Cancer Therapy.","authors":"Jennifer N Choi, Mario Lacouture, Anneke Andriessen, Alice Ho, Beth McLellan, Edith Mitchell, Jonathan Leventhal","doi":"10.36849/JDD.84821","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In 2024, over 2 million patients will be diagnosed with cancer in the United States, with prostate cancer and breast cancer representing the leading diagnoses in men and women, respectively. Hormonal therapy is a mainstay treatment for hormone-dependent cancers but is associated with cutaneous adverse events. These include accelerated signs of aging, xerosis and pruritus, brittle nails, androgenic alopecia, and hirsutism. All clinicians involved in the care of these patients play an essential role in managing treatment-related cutaneous adverse events to minimize the burden on patients and improve their quality of life.</p><p><strong>Objectives: </strong>To develop a multidisciplinary, physician-developed algorithm to guide the care of patients who develop cutaneous hormonal therapy-related adverse events.</p><p><strong>Methods: </strong>A panel of advisors was selected, and a systematic literature review generated evidence to develop a treatment algorithm for managing cutaneous hormonal therapy-related adverse events via a modified Delphi process. The algorithm was developed based on the assembled evidence coupled with the panel's experience and opinion.</p><p><strong>Results: </strong>An algorithm that tailors the prevention and management of cutaneous hormonal therapy-related adverse events in cancer patients used the CTCAE v.5 grading of cancer therapy-related skin disorders. Suggested management recommendations supplement the algorithm.</p><p><strong>Conclusions: </strong>Prevention, recognition, and treatment of cutaneous hormonal therapy-related adverse events through the use of a physician-developed algorithm may limit treatment interruption, improve patient outcomes, and optimize the quality of life in patients on hormonal cancer therapy. J Drugs Dermatol. 2025;24:4(Suppl 2):s3-14.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"84821s3-84821s14"},"PeriodicalIF":1.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.84821","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: In 2024, over 2 million patients will be diagnosed with cancer in the United States, with prostate cancer and breast cancer representing the leading diagnoses in men and women, respectively. Hormonal therapy is a mainstay treatment for hormone-dependent cancers but is associated with cutaneous adverse events. These include accelerated signs of aging, xerosis and pruritus, brittle nails, androgenic alopecia, and hirsutism. All clinicians involved in the care of these patients play an essential role in managing treatment-related cutaneous adverse events to minimize the burden on patients and improve their quality of life.
Objectives: To develop a multidisciplinary, physician-developed algorithm to guide the care of patients who develop cutaneous hormonal therapy-related adverse events.
Methods: A panel of advisors was selected, and a systematic literature review generated evidence to develop a treatment algorithm for managing cutaneous hormonal therapy-related adverse events via a modified Delphi process. The algorithm was developed based on the assembled evidence coupled with the panel's experience and opinion.
Results: An algorithm that tailors the prevention and management of cutaneous hormonal therapy-related adverse events in cancer patients used the CTCAE v.5 grading of cancer therapy-related skin disorders. Suggested management recommendations supplement the algorithm.
Conclusions: Prevention, recognition, and treatment of cutaneous hormonal therapy-related adverse events through the use of a physician-developed algorithm may limit treatment interruption, improve patient outcomes, and optimize the quality of life in patients on hormonal cancer therapy. J Drugs Dermatol. 2025;24:4(Suppl 2):s3-14.
期刊介绍：
The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.
We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality.
Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
